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A B S T R A C T
Background: Hyperthermic intraperitoneal chemotherapy (HIPEC) poses a widely used and accepted treatment
option for patients with peritoneal carcinomatosis of gastrointestinal tumors. In contrast to the well-described
risks and complications of intravenous cytostatic drugs, literature oﬀers only scarce information of serious
complications following HIPEC. To our knowledge no other description of rapid progressive pulmonary hy-
pertension (PH) and consecutive respiratory failure following HIPEC have been described in current literature.
Case presentation: A 48-year-old female suﬀering from a recurrent appendix-carcinoma developed progressive
dyspnea and fatigue six weeks after multivisceral abdominal resection and HIPEC. Medical examinations in-
cluded laboratory-checks, non-invasive imaging, scintigraphy as well as invasive examinations (left-/right-heart-
catheterization) and conﬁrmed PH of unknown origin to be the cause of dyspnea. The patient died nine days
after admission of respiratory failure and rapid deterioration as a result of aggravating PH.
Conclusion: Rapid progressive respiratory insuﬃciency due to PH following HIPEC procedure might represent a
rare complication, but must be considered because of the high clinical impact. Further studies are necessary to
investigate the correlation between HIPEC and PH.
1. Background
Hyperthermic intraperitoneal chemotherapy (HIPEC) and cytor-
eductive surgery (CRS) represent a widely accepted therapeutic ap-
proach in oncological surgery. Severe side eﬀects are known, but to our
knowledge no other case of lethal rapid progressive pulmonary hy-
pertension (PH) and respiratory failure following HIPEC procedure is
described. We screened medical databases for known side eﬀects of
oxaliplatin, 5-Fluorouracil (5-FU), CRS and HIPEC and searched for
possible reasons of PH following the HIPEC procedure.
2. Case report
This case report was written in line with the SCARE criteria [1].
Written informed consent for publishing these data was obtained from
the patient.
We present the case of a 48-year old female suﬀering from a me-
tastasized carcinoid of the appendix, initially diagnosed in 2010. After
primary surgery in 2010 (appendectomy and follow-up resection), the
patient underwent additional surgical interventions ﬁve years later
caused by a local relapse (adhesiolysis, hysterectomy, bilateral adnex-
ectomy, peritonectomy), followed by adjuvant intravenous che-
motherapy with Oxaliplatin and 5-FU. In 2016, a third major surgical
intervention was performed including complete parietal and partial
mesenterial peritonectomy, partial resection of the small intestine,
subtotal colectomy with terminal ascendostomy (“Hartmann's proce-
dure”), cholecystectomy and omentectomy. This surgical intervention
was combined with a HIPEC therapy, initiated with preoperative in-
travenous injection of 5-FU (400 mg*m−2) and Calciumfolinat (20
mg*m−2) followed by an intraabdominal HIPEC with Oxaliplatin (300
mg*m−2). All procedures were performed by experienced senior phy-
sicians, anesthesiologists and surgeons in an university hospital setting.
The patient recovered without surgical complications from that major
procedure and was discharged in good clinical condition for further
ambulatory treatment.
Six weeks after HIPEC procedure she developed dyspnea and pro-
gressive fatigue leading to hospital admission via ambulance in sig-
niﬁcantly reduced general condition. The next day, she evolved a sinus-
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tachycardia (up to 150 bpm) with a preserved blood pressure and an
increasing oxygen demand accompanied by rapid deterioration of the
patient's clinical status. In view of the severe progress, the patient was
admitted to the anesthesiological intermediate care unit for further
diagnostics and therapy. Firstly, severe infection was suspected, but
could be excluded by laboratory and radiologic ﬁndings. Secondly,
transthoracic echocardiography was performed in order to assess the
patient's hemodynamic status. It revealed neither signs of left ven-
tricular dilatation nor hypertrophy and a good global systolic function
(left ventricular ejection fraction 65%) without regional motion ab-
normalities. The mitral and aortic valve as well as the left atrial and
ventricular diameter seemed unsuspicious. In contrast, the right heart
showed under tachycardia (120 bpm) a slightly dilated ventricle and a
nearly preserved right ventricular pump function (tricuspid annular
plane systolic excursion (TAPSE) 18 mm). Right ventricular pressure
was moderately elevated, quantiﬁed through a minor tricuspid in-
suﬃciency (systolic pulmonary artery pressure (PAPsys)
35 mmHg + central venous pressure (CVP), estimated 8 mmHg [2]).
Laboratory results revealed elevated cardiac enzymes and highly pa-
thologic D-Dimers (Table 1).
Based on the clinical examination and diagnostic ﬁndings, pul-
monary artery embolism has been suspected and therefore a contrast-
enhanced thoracic computer tomography (CT) performed. Consistent to
the echocardiographic ﬁndings the right heart was enlarged but sur-
prisingly neither subsegmental nor central pulmonary artery embolism
could be detected. Both sides of the lungs showed concomitant atypical
interstitial and partially alveolar edema, consistent with an interstitial
pneumonitis (Figs. 1b and 2a). Ventilation-/perfusion-scintigraphy was
performed in order to exclude also peripheral pulmonary artery em-
bolism. Some areas of combined reduced ventilation/perfusion were
compatible with the mentioned alveolar consolidations in the CT, but
no signs of arterial embolism could be detected. Because of the growing
suspicion of signiﬁcant PH as possible reason for the persistent symp-
toms, a left-/right heart catheterization was performed. While the
coronary arteries and the left ventricular function remained un-
suspicious, the right heart catheterization showed increased pressure-/
resistance proportions (mean pulmonary artery pressure 34 mmHg,
pulmonary vascular resistance 530 dyn*sec*cm−5), narrowed cardiac
output ((CO) 1.9 L*min−1*m−2) and minor pulmonary venous con-
gestion (pulmonary capillary wedge pressure 13mmHg). Regarding the
positive proof of PH, oral therapy with Sildenaﬁl was initiated. How-
ever, over the following ﬁve days initial PAPsys increased from
35 mmHg up to 55 mmHg (+CVP, estimated 5 mmHg, moderate tri-
cuspid valve insuﬃciency), accompanied by moderately enlarged right-
sided cavities (right atrium 14 cm [2], right ventriclebasal 37 mm).
While the right ventricular function kept preserved (TAPSE 19 mm, S′
17 cm*sec−1, Tei index 0.53), moderate paradoxic movement of the
septum with D-sign of the right ventricle increased. Furthermore the
right ventricular outﬂow tract ﬂow-proﬁle appeared severely impaired
(AT 52ms, AT/ET 0.22), whereas inferior vena cava and liver veins
were not extended. Simultaneously, blood gas analysis showed under
noninvasive oxygen insuﬄation a progressive decrease of respiratory
parameters (under 3 l O2/min: admission: pO2: 85.4 mmHg, 36 hours
later: pO2: 69.9 mmHg). Facing the aggravating precapillary PH and
persistent reduced right ventricular function (CO 1.9 l/min/m2) Silde-
naﬁl administration was switched from oral to continuous intravenous
application. Unfortunately, the patient's respiratory situation did not
improve under the PDE-5-inhibitor therapy and was aggravated by the
patient's refusal to tolerate non-invasive ventilation. Considering the
patient's debilitated general condition, her hopeless prognosis (multiple
metastasis of bones, retroperitoneal/iliacal/inguinal lymphatic nodes,
liver as well as peritoneal carcinomatosis) and most important her wish
for palliative care, we stood back from further escalation of therapy.
The patient died nine days after admission of global respiratory and
right ventricular failure (Clavien-Dindo Classiﬁcation Grade V [3]). The
relatives did not acquiesce an autopsy to clarify the underlying cause of
the PH. Considering the rapid progress and radiologic ﬁndings, inter-
stitial pneumonitis led possibly to sequential development of PH.
Table 1
Overview of laboratory ﬁndings during the patient's hospital stay. Abbreviations: BNP: brain natriuretic peptide; CK: creatine kinase; CK-MB: creatine kinase myoglobin; CRP: C-reactive
protein; HB: hemoglobin; PAD: post-admission day; PCT: procalcitonin.
Value Unit (standard values) Admission day PAD 2 PAD 3 PAD 5 PAD 6 PAD 7 PAD 8 PAD 10
CK 12–140 (U/I) 214 145 142 145 149 160 189 177
CK-MB 0–12 (U/I) 313 260 276 296
Troponin I 0–0.05 (μg/L) 1.88 0.62 0.26 0.08
BNP 0–57 (pg/mL) 347 499 512
Myoglobin 0–120 (μg/L) 47 26 27 35
D-Dimer 0–0.49 (μg/mL FEU) 16.46 17.45 18.99 19.27
CRP 0–1.0 (mg/L) 24.22 32.83 38.48 54.25 147.39 122.48 106.64 157.37
PCT 0–0.5 (μg/L) < 0.5 0.7 1.1 1.2
Leucocytes 3.9–10.2 (giga/L) 14 8.8 8.0 12.4 11.3 11.4 14.4 25.6
Hb 12.0–15.4 (g/L) 13.4 11.9 11.1 12.1 11.4 11.4 12 11.2
Fig. 1. Axial planes of thoracic contrast enhanced
computed tomography eight days (a) and six
weeks (b) after CRS and HIPEC. Eight days after
surgery both lungs are inconspicuous except for
minor dystelectatic pneumonia of both lower
lobes and adjacent small pleural eﬀusions. The
heart shows regular dimensions. Six weeks after
CRS and HIPEC the data display extensive aty-
pical interstitial and partly alveolar edema. No
signs of pulmonary artery embolism can be de-
tected (not visible in demonstrated plane).
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Retrospectively, neither signs of cardiac failure nor PH have been
detected in the patient's medical history prior to the HIPEC procedure.
She was non-smoking, able to hike 40 km in two days and covered 2000
m in height without dyspnea, discomfort or chest pain. Prior the re-
ported hospitalization, she underwent multiple medical examinations
(chest X-rays, electrocardiography, thoracic CTs), but none depicted
signs of right ventricular failure or PH. Due to the good clinical con-
dition, preoperative anesthesiological assessment did neither include
echocardiography nor spirometry. Immediately after the HIPEC proce-
dure the patient developed clinical and radiographic signs of an inter-
stitial pulmonary edema that can be explained by liberal peri- and
postoperative volume management and a major postsurgical capillary
leakage, rather than by cardiac failure.
3. Discussion
3.1. HIPEC
We report the case of a 48-year-old woman who died of right ven-
tricular and respiratory failure six weeks after multivisceral resection
and HIPEC. Rapid aggravation of interstitial pneumonitis and PH could
be unveiled as the underlying cause of death and confronted us with an
unknown scenario within this clinical constellation. Providing critical
patient selection and a strict safety regimen, CRS and HIPEC represent
widely applied and well-established procedures in the treatment of
diﬀerent cancer entities like colon- and gastric cancer [4–7]. Compared
to palliative surgery and/or systemic chemotherapy, evidence supports
a beneﬁcial eﬀect of HIPEC in matter of disease-free and overall sur-
vival (with/without early post-operative intraperitoneal chemotherapy)
[8–12]. If applied to selected patients with peritoneal carcinomatosis of
gastrointestinal malignancies, a treatment-related mortality as low as
1.5% was described [13]. Current data revealed a HIPEC-associated
mortality of 4.8%, which is still comparable to major gastrointestinal
surgery [14]. Increased HIPEC-related morbidity compared to the
standard surgical approach for the treatment of advanced gastric cancer
(OR=1.67, 95%-CI: 1.13–2.45, p=0.009) was recently reported,
while respiratory complications diﬀered not signiﬁcantly between both
groups (surgery alone vs. surgery and HIPEC, p > 0.05) [15].
3.2. Pulmonary hypertension
Regarding the period of 6 weeks of good initial recovery after CRS
and HIPEC, the patient's inconspicuous cardiac and pulmonary history
as well as the rapid aggravation of the patient's clinical condition and
cardio-pulmonary situation, raised suspicion onto a thromboembolic
aﬀection or an infectious cause. Low infectious laboratory values,
normal body temperature, lack of infectious signs in the radiographic
examinations in addition to unsuspicious microbiological ﬁndings did
neither support the suspected diagnosis of severe infection nor did they
explain the pronounced clinical status.
Cancer related thromboembolism represents a relevant complica-
tion of solid tumor diseases that worsens the patient's outcome if not
recognized and treated adequate [16,17]. A retrospective single center
study identiﬁed an age of> 40 years, advanced cancer stage, active
chemo-therapy, use of erythropoetin for anemia and underdosage of
thrombosis prophylaxis as risk factors for cancer related thromboem-
bolism in patients suﬀering of solid tumor diseases [16]. The described
patient met, except for the usage of erythropoetin and the underdosage
of thrombosis prophylaxis, all of these risk factors. Despite the high-risk
proﬁle, extended radiographic imaging and laboratory tests ruled out
an acute thromboembolic complication as cause for the rapid onset of
PH. Moreover, approximately 25% of deceased cancer patients show
tumor embolism in the pulmonary circulation leading to tumor mi-
gration, microangiopathy and subsequently also to PH [18]. Particu-
larly associated with PH are gastric, breast, ovarial, pulmonary, renal
and colon cancer entities. Nevertheless, no signs of tumor embolism as
possible cause of a beginning chronic thromboembolic PH (CTEPH)
could be detected within the presented patient. Based on these results,
we sought for alternative underlying pathomechanisms explaining the
further aggravating PH with consecutive respiratory and right ven-
tricular failure of unknown origin. Considering the world health orga-
nization classiﬁcation of PH [19], we searched without success for signs
of venous occlusive disease, portopulmonary hypertension, congestive
heart failure, chronic infectious diseases or genetic disorders leaving
the diﬀerential diagnosis of acute pulmonary diseases or drug induced
PH.
Initial thoracic CT showed extensive atypical interstitial and partly
alveolar edema of the lung. These diagnostic ﬁndings were not
Fig. 2. Axial planes of thoracic non-enhanced-CT
(a) and positron emission tomography (PET)
(b–d) six weeks after CRS and HIPEC procedure.
Fig. 2 displays extensive metastasis and in-
ﬂammatory inﬁltrates in both upper lobes in
diﬀerent non-enhanced axial planes (a, b) and in
PET-visualization (c). Fig. 2 d shows a sagittal
view of the body. Next to the inﬂammatory al-
teration of both lungs, multiple metastases of the
lungs, bones and bone marrow can be identiﬁed.
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concordant to the severity and the development of the PH. Positron-
emission-tomography (PET) presented a change of the pulmonary dis-
semination with extensive inﬂammatory activity in both upper lobes
(Fig. 2 b–d). The institutional pulmonary radiological specialist eval-
uated these ﬁndings as pneumonitis, accordable to a drug induced in-
terstitial pneumonitis (patchy ground glass opacities, reticular in-
creased streaking, pleural eﬀusions). The inﬂammatory pattern were
not detectable directly after, but on day eight after admission to the
hospital. Subsequently, possible drug related mechanisms leading to
pulmonary inﬂammation and PH were examined.
3.3. 5-Fluorouracil
Because of symptomatic polyneuropathy, intravenous che-
motherapy with Oxaliplatin and 5-FU was stopped after two cycles six
months prior to the CRS and HIPEC procedure. The side eﬀect proﬁle of
Calciumfolinat and 5-FU did neither indicate pulmonary complications,
PH nor pulmonary ﬁbrosis. Performing a literature search, we were not
able to ﬁnd information about pulmonary complications and/or side
eﬀects that are singularly connected to 5-FU or Calciumfolinat [search
items: development PH, respiratory failure, pulmonary complications,
complications + HIPEC, complications + CRS, connected to in-
travenous/intraabdominal 5-FU or Calciumfolinat; Databases: PubMed,
Embase, Cochrane Library]. Already in 1979, Fielding et al. portrayed a
lethal case of emerging interstitial ﬁbrosis following intravenous ap-
plication of 5-FU and Mitomycin [20]. After exclusion of other etiolo-
gical factors, they stated a connection between the chemotherapy and
the ﬁbrosing alveolitis. Another case report describes the onset of an
acute lung injury associated with systemic Oxaliplatin and 5-FU che-
motherapy. Similar to the reported patient, an organizing diﬀuse al-
veolar damage pattern was found. Unfortunately, a diﬀerentiation be-
tween both chemotherapeutical drugs as the causing agent was not
possible [21]. Chan et al. described a third case in which a combination
of Oxaliplatin and 5-FU for intravenous chemotherapy was connected
to symptomatic pulmonary ﬁbrosis in a patient with preexisting
asymptomatic interstitial lung disease [22]. A review of the literature
indicated that 5-FU is only associated to pulmonary side eﬀects when
used as co-medication of Oxaliplatin or Mitomycin. While the pul-
monary tissue appears not to be impaired by 5-FU, the cardiotoxic ef-
fects seem to be distinctively more signiﬁcant, ranging from 7.6% up to
15% in patients with preexisting coronary artery disease [23]. These
cardiotoxic eﬀects seem to be based on endothelial damage and/or
vasoconstriction of vascular smooth muscle cells. In-vitro-evidence
(rabbits) shows a 5-FU-associated endothelium-independent vasocon-
striction of aortic vascular smooth muscle cells [24]. Furthermore,
Suedhoﬀ et al. were able to show an arterial contraction (brachial ar-
tery) analogue to 5-FU application [25]. Polk et al. summarize the
pathomechanisms leading to cardiotoxic eﬀects of 5-FU as a result of
endothelial injury followed by thrombosis, increased metabolism
leading to energy depletion and ischemia, oxidative stress causing
cellular damage and coronary artery spasm leading to myocardial
ischemia [26]. Considering the aforementioned studies, 5-FU could
possibly result in PH, if pulmonary vessels would be aﬀected. But to our
knowledge no data exists, which identiﬁed an isolated connection be-
tween 5-FU and pulmonary arterial endothelial damage and/or vaso-
constriction.
3.4. Oxaliplatin
Oxaliplatin represents an established chemotherapeutical drug with
an adverse side eﬀect proﬁle including peripheral sensory neuropathy,
hematological toxicity, and allergic reactions [27]. When used for in-
travenous chemotherapy, Oxaliplatin is known, although infrequent, to
cause severe pulmonary complications like interstitial pulmonary ﬁ-
brosis [21,28–30] or pneumonitis [7,31–33]. But, a direct damaging
eﬀect of Oxaliplatin on lung tissue or vessels has yet not been identiﬁed.
Previous studies suggest that therapy with Oxaliplatin can lead to a
reduction of serum-levels of glutathione, which possibly results in
oxidative stress of the pulmonary vessels leading to interstitial pneu-
monitis and pulmonary ﬁbrosis [34,35]. Pulmonary ﬁbrosis and grade
IV pulmonary toxicity were reported in less than 1% of patients treated
with Oxaliplatin [27,36]. Twenty-six descriptions of Oxaliplatin-related
pulmonary toxicity have been described in the current literature, while
sixteen of these cases (61.5%) were fatal [27]. Keldsen et al. in-
vestigated the pulmonary side eﬀects in a prospective setting for pa-
tients with colorectal cancer and adjuvant Oxaliplatin therapy and
showed only a small decrease in spirometric Tiﬀeneau's ratio (forced
expiratory volume in one second/forced vital capacity ratio (FEV1/
FVC), p= 0.03), while neither other pulmonary parameters nor re-
spiratory status worsened [37]. No other similar case descriptions or
surveys of PH after HIPEC procedure with Oxaliplatin have been de-
tected in the literature search [search items: development PH, pul-
monary/respiratory failure, pulmonary/respiratory complications,
complications + HIPEC, complications + CRS, connected to in-
travenous/intraabdominal Oxaliplatin; Databases: PubMed, Embase,
Cochrane Library]. Overall, in consequence of the little existing data
the extent and relevance of pulmonary toxicity of Oxaliplatin remains
not quantiﬁable. The rare but potentially lethal side eﬀects exhibit
currently only few identiﬁed risk factors such as preexisting lung dis-
ease or smoking history [38]. In contrast to other chemotherapeutics
like Bleomycin or Busulfan, that are known for their pulmonary toxi-
city, treatment guidelines for Oxaliplatin induced pulmonary compli-
cations are not available [39,40]. The wide use of Oxaliplatin, in mainly
multidrug treatment regimens, complicates the diﬀerentiation of po-
tential singular drug side eﬀects. On the contrary, several case reports
showed a resolution of the pulmonary complications after exclusion of
Oxaliplatin from the intravenous chemotherapeutic drug regime
[5,28,41]. Nevertheless the current data is connected to intravenous
usage of Oxaliplatin and does not provide further information about its
intraabdominal application in HIPEC patients [29–31,33,37,40,42,43].
Although the absorption of intraabdominal administered cytostatic
drugs is very low, a certain amount is still systematically incorporated
[10]. The reabsorption of Oxaliplatin might be facilitated by its high
absorption rate in comparison to 5-FU even though it exhibits a higher
molecular weight (molecular weight 397 g/mol (Oxaliplatin) vs. 130 g/
mol (5-FU), area under the curve ratio of systemic vs. intraperitoneal
resorption of 1:25 ml/min/1,73 m2 (Oxaliplatin) and 1:250 ml/min/
1,73 m2 (5-FU)) [44]. Multivisceral surgery accompanied by HIPEC
procedure generates a vast ﬁeld of damaged tissue resulting in barrier
disturbances and peritoneal leakage. These eﬀects lead to signiﬁcant
variations of the peritoneal absorption and plasmatic Oxaliplatin con-
centrations as described in former studies [45–47]. In the presented
case the operative procedure lasted over 10 hours with extensive sur-
gical trauma, which might have led to relevant Oxaliplatin-absorption.
In the context of systemic application, cumulative dose of Oxaliplatin
does not appear to be a risk factor for following pulmonary complica-
tions, as these were observed after the ﬁrst cycle of chemotherapy up to
more than 12 cycles [41,48]. In our opinion, based on its side eﬀect
proﬁle and a possible peritoneal reabsorption, Oxaliplatin is the most
likely cause of pulmonary damage leading to PH in the presented pa-
tient, even though we are not able to exclude 5-FU or other drugs as
relevant co-factors.
Moskovitz stated, that drug-induced PH is a diagnosis of exclusion,
which remains a challenging task caused by an overlap of symptoms
and the diﬃcult retracing of the causative drug in a multi therapeutic
regime [36]. The reported patient presented rapid structural pulmonary
change after HIPEC procedure resulting in progressive PH and con-
secutive right ventricular impairment. Even though we were able to
perform extended examinations, the time from the patient's diagnosis to
her death was to short to prove our hypothesis of Oxaliplatin-induced
lung damage with consecutive PH.
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4. Conclusion
Rapid onset and progress of PH and interstitial pneumonitis, might
be associated with Oxaliplatin-containing HIPEC therapy. Oxaliplatin-
induced interstitial lung diseases should be considered for the diﬀer-
ential diagnosis of respiratory disorders following HIPEC procedure.
Further investigations of chemotherapeutical-induced side eﬀects on
the respiratory system are necessary as well as further experimental
studies in order to clarify the underlying mechanisms of possible
HIPEC-induced lung injury.
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